Search Results - Muhammad Rehman

Muhammad Rehman

Muhammad Rehman (; born 5 January 1944) is a Pakistani cardiac surgeon. Rehman hails from the village Budhni in Peshawar. He is the founder of Rehman Medical Institute (RMI), Rehman Medical College and Rehman Medical Center.

Rehman obtained his MBBS degree from the Khyber Medical College. He completed his training in Cardiothoracic surgery in 1975 from Royal College of Surgeons Edinburgh. He is the leading Cardiothoracic surgeon in Pakistan. His experience in the field of Cardiac Surgery started in July 1974 as Registrar in Cardiothoracic Surgery in The London Chest Hospital. In January 1975 he moved on to work as Registrar in Brompton Hospital, London. He then decided to move back to Pakistan and started working in the National Institute of Cardiovascular Diseases, Karachi as Consultant Cardiac Surgeon in August 1975. He remained the Head of the Cardiac Surgical Department and served his department for 28 years, retiring as Professor of Cardiac Surgery in January 2004.

While working there, Professor Rehman remained the Dean Faculty of Cardiac Surgery in the College of Physicians and Surgeons Pakistan and also served as the President of the Pakistan Society of Cardiovascular and Thoracic Surgeons. He was the patron of the "Friends of Cardiac Surgery", a non-profit organization supporting the Cardiac Unit at the Civil Hospital, Karachi. He is also the founder editor of the Journal of Cardiovascular and Thoracic Surgeons. Provided by Wikipedia
  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    Interplay Between MW, ΩCDMh2, and g−2μ in Flavor Symmetry–Based Supersymmetric Models by Sajid Israr, Mario E. Gómez, Muhammad Rehman, Yasir Arafat

    Published 2025-01-01

    We study the phenomenological implications of the minimal supersymmetric standard model (MSSM) augmented by a nonabelian flavor symmetry labeled as sMSSM. Incorporating this flavor symmetry allows for a significant reduction in the original plethora of free parameters present in the MSSM, ultimately...

    Full description

    Get full text
    Article
  2. 2

    Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to we... by Goran Babic, Hideto Kameda, Rieke Alten, Bogdan Batko, Tomas Hala, Sebastiao C Radominski, Vira Tseluyko, Carol Cronenberger, Sarah Hackley, Muhammad Rehman, Oliver von Richter, Min Zhang, Stanley Cohen

    Published 2019-05-01

    Objective To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade®; ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were sw...

    Full description

    Get full text
    Article